Italian Association of Hospital Cardiologists practical guidance for sodium-glucose cotransporter 2 inhibitors use in patients with heart failure.

IF 1.7 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

European Heart Journal Supplements Pub Date : 2023-05-18 eCollection Date: 2023-05-01 DOI:10.1093/eurheartjsupp/suad107

Stefania Angela Di Fusco, Antonella Spinelli, Stefano Aquilani, Nunzia Borrelli, Gianmarco Iannopollo, Michele Massimo Gulizia, Domenico Gabrielli, Fabrizio Oliva, Furio Colivicchi

{"title":"Italian Association of Hospital Cardiologists practical guidance for sodium-glucose cotransporter 2 inhibitors use in patients with heart failure.","authors":"Stefania Angela Di Fusco, Antonella Spinelli, Stefano Aquilani, Nunzia Borrelli, Gianmarco Iannopollo, Michele Massimo Gulizia, Domenico Gabrielli, Fabrizio Oliva, Furio Colivicchi","doi":"10.1093/eurheartjsupp/suad107","DOIUrl":null,"url":null,"abstract":"<p><p>Sodium-glucose cotransporter 2 inhibitors (SGLT2-is) have recently been included among the first-line drugs for the treatment of heart failure with reduced ejection fraction. International guidelines recommend SGLT2-i use in association with neuro-hormonal modulators (renin-angiotensin blockers, beta blockers, and aldosterone antagonists). Although SGLT2-is are well tolerated, it is important to know potential side effects and conditions that may lead to an increased risk of adverse events in order to maximize clinical benefits. The aim of this Italian Association of Hospital Cardiologists document is to briefly report clinical evidence that supports SGLT2-i use in patients with heart failure and provide practical indications for clinical implementation.</p>","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":"25 Suppl D","pages":"D287-D293"},"PeriodicalIF":1.7000,"publicationDate":"2023-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/99/30/suad107.PMC10194818.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Heart Journal Supplements","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/eurheartjsupp/suad107","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/5/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Sodium-glucose cotransporter 2 inhibitors (SGLT2-is) have recently been included among the first-line drugs for the treatment of heart failure with reduced ejection fraction. International guidelines recommend SGLT2-i use in association with neuro-hormonal modulators (renin-angiotensin blockers, beta blockers, and aldosterone antagonists). Although SGLT2-is are well tolerated, it is important to know potential side effects and conditions that may lead to an increased risk of adverse events in order to maximize clinical benefits. The aim of this Italian Association of Hospital Cardiologists document is to briefly report clinical evidence that supports SGLT2-i use in patients with heart failure and provide practical indications for clinical implementation.

Abstract Image

查看原文本刊更多论文

意大利医院心脏病专家协会关于心力衰竭患者使用钠-葡萄糖共转运体 2 抑制剂的实用指南。

钠-葡萄糖共转运体 2 抑制剂（SGLT2-is）最近被列为治疗射血分数降低型心力衰竭的一线药物。国际指南建议 SGLT2-i 与神经激素调节剂（肾素-血管紧张素阻滞剂、β 受体阻滞剂和醛固酮拮抗剂）联合使用。虽然 SGLT2-i 的耐受性良好，但了解潜在的副作用和可能导致不良事件风险增加的情况也很重要，这样才能最大限度地提高临床疗效。这份意大利医院心脏病专家协会文件旨在简要报告支持在心力衰竭患者中使用 SGLT2-i 的临床证据，并提供临床实施的实用指征。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Heart Journal Supplements 医学-心血管系统

CiteScore

3.00

自引率

0.00%

发文量

575

审稿时长

12 months

期刊介绍： The European Heart Journal Supplements (EHJs) is a long standing member of the ESC Journal Family that serves as a publication medium for supplemental issues of the flagship European Heart Journal. Traditionally EHJs published a broad range of articles from symposia to special issues on specific topics of interest. The Editor-in-Chief, Professor Roberto Ferrari, together with his team of eminent Associate Editors: Professor Francisco Fernández-Avilés, Professors Jeroen Bax, Michael Böhm, Frank Ruschitzka, and Thomas Lüscher from the European Heart Journal, has implemented a change of focus for the journal. This entirely refreshed version of the European Heart Journal Supplements now bears the subtitle the Heart of the Matter to give recognition to the focus the journal now has. The EHJs – the Heart of the Matter intends to offer a dedicated, scientific space for the ESC, Institutions, National and Affiliate Societies, Associations, Working Groups and Councils to disseminate their important successes globally.